- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05913713
HIIT después de la quimioterapia contra el cáncer de mama
Entrenamiento de intervalos de alta intensidad: optimización de la terapia de ejercicios para mitigar el riesgo de enfermedades cardiovasculares después de la quimioterapia contra el cáncer de mama
Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training compared to moderate-intensity continuous training on cardiovascular rehabilitation in breast cancer survivors.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32611
- Integrative Cardiovascular Physiology Laboratory, University of Florida
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- female patients based on biological sex
- 18 to 85 years of age
- diagnosis of primary, invasive, non-metastatic, stages I-III breast cancer
- completed chemotherapy for breast cancer (anthracycline, alkylating agent and/or taxane) more than 6 months but less than 18 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment and during study participation
- absence of contraindications to exercise or to participate in study
- study clinician approval
Exclusion Criteria:
- do not meet inclusion criteria
- scheduled to receive surgery or radiation therapy during the intervention period
- any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
- lymphedema stage ≥2 prior to study enrollment
- are pregnant
- current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: High Intensity Interval Training (HIIT)
Supervised home-based high-intensity interval training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks. |
Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period. After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises. |
|
Experimental: Moderate Intensity Continuous Training (MICT)
Supervised home-based moderate-intensity continuous training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks. |
Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period. After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises. |
|
Otro: Usual Care (UC)
Research participants will continue their habitual physical activity for the duration of the study. Once they complete the study, they will have the opportunity to perform supervised HIIT or MICT at home for 3 days/week for 12 weeks (research participants can choose either type of exercise). |
Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period. After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in brachial FMD
Periodo de tiempo: Baseline, Following a 12-week intervention period, Following a 12-week observation period
|
Flow-mediated dilation (FMD) is an established non-invasive measure of endothelial function. Brachial artery FMD will be determined via ultrasonography in response to reactive hyperemia following 5-min forearm ischemia. |
Baseline, Following a 12-week intervention period, Following a 12-week observation period
|
|
Change in cardiac function (global longitudinal strain)
Periodo de tiempo: Baseline, Following a 12-week intervention period, Following a 12-week observation period
|
Global longitudinal strain is a marker of acute subclinical cardiotoxicity and is recommended for monitoring cancer patients at risk of cancer therapy-related cardiac dysfunction. |
Baseline, Following a 12-week intervention period, Following a 12-week observation period
|
|
Percent completed vs. planned exercise frequency
Periodo de tiempo: Throughout the 12 weeks of supervised home-based exercise training
|
The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise sessions/week. |
Throughout the 12 weeks of supervised home-based exercise training
|
|
Percent completed vs. planned exercise duration
Periodo de tiempo: Throughout the 12 weeks of supervised home-based exercise training
|
The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise min/session. |
Throughout the 12 weeks of supervised home-based exercise training
|
|
Percent completed vs. planned exercise intensity
Periodo de tiempo: Throughout the 12 weeks of supervised home-based exercise training
|
The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise intensity/session. |
Throughout the 12 weeks of supervised home-based exercise training
|
|
Number of participants who experience adverse events as defined by most recent CTCAE throughout the exercise intervention
Periodo de tiempo: Throughout the 12 weeks of supervised home-based exercise training
|
To evaluate safety plans are in place for determination and monitoring of adverse events according to the most recent National Cancer Institute Common Terminology Criteria for Adverse Events. Classification for seriousness, expectedness, severity and relationship to study intervention will be based on the NIH provided definitions. |
Throughout the 12 weeks of supervised home-based exercise training
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Demetra Christou, PhD, University of Florida
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IRB202300460 -N
- 1R21AG078995-01A1 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .